Search

Search Constraints

You searched for: Author/Creator Henrickson, Michael

Search Results

1. 170 Safety and efficacy of subcutaneous tocilizumab in patients with systemic and polyarticular juvenile idiopathic arthritis. (12th April 2019)

2. A plausibly causal functional lupus-associated risk variant in the STAT1–STAT4 locus. (18th April 2018)

3. A6: Tapering and Withdrawal of Tocilizumab in Patients With Systemic Juvenile Idiopathic Arthritis in Inactive Disease: Results From an Alternative Dosing Regimen in the TENDER Study. Issue 11 (March 2014)

4. Validation of the Cutaneous Lupus Erythematosus Disease Area and Severity Index and pSkindex27 for use in childhood-onset systemic lupus erythematosus. Issue 1 (17th November 2018)

5. FRI0181 THE PLUTO STUDY: INTRAVENOUS BELIMUMAB IN CHILDREN WITH SYSTEMIC LUPUS ERYTHEMATOSUS. (June 2019)

6. AB1065 THE UTILISATION OF S100 PROTEINS TESTING IN PEDIATRIC RHEUMATOLOGY PATIENTS IN A TERTIARY CARE INSTITUTION AND IMPLICATIONS FOR CARE. (June 2019)

7. THU0516 LONG-TERM SAFETY OF SUBCUTANEOUS TOCILIZUMAB ADMINISTRATION IN SYSTEMIC AND POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS. (June 2019)

8. Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension. Issue 4 (17th March 2010)

9. A6: Tapering and Withdrawal of Tocilizumab in Patients With Systemic Juvenile Idiopathic Arthritis in Inactive Disease: Results From an Alternative Dosing Regimen in the TENDER Study. Issue Volume 66:Issue(2014)supplement 3 (March 2014)

10. Keutel syndrome: Report of two novel MGP mutations and discussion of clinical overlap with arylsulfatase E deficiency and relapsing polychondritis. Issue 4 (23rd January 2014)